CLBS Annual SG&A
$11.37 M
+$1.48 M+14.94%
31 December 2021
Summary:
As of January 31, 2025, CLBS annual selling, general & administrative expenses is $11.37 million, with the most recent change of +$1.48 million (+14.94%) on December 31, 2021. During the last 3 years, it has risen by +$1.98 million (+21.05%).CLBS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLBS Quarterly SG&A
$3.95 M
+$466.00 K+13.39%
01 September 2022
Summary:
As of January 31, 2025, CLBS quarterly selling, general & administrative expenses is $3.95 million, with the most recent change of +$466.00 thousand (+13.39%) on September 1, 2022. Over the past year, it has increased by +$1.10 million (+38.83%).CLBS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLBS TTM SG&A
-$1.88 B
-$55.03 M-3.02%
01 September 2022
Summary:
As of January 31, 2025, CLBS TTM selling, general & administrative expenses is -$1.88 billion, with the most recent change of -$55.03 million (-3.02%) on September 1, 2022. Over the past year, it has dropped by -$1.89 billion (-16829.50%).CLBS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLBS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.9% | +38.8% | -10000.0% |
| 3 y3 years | +21.1% | +90.9% | -10000.0% |
| 5 y5 years | -3.2% | +34.1% | -10000.0% |
CLBS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -63.1% | -67.6% | -5360.2% |
Caladrius Biosciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | $3.95 M(+13.4%) | $13.47 M(+8.9%) |
| June 2022 | - | $3.48 M(+4.2%) | $12.37 M(+5.7%) |
| Mar 2022 | - | $3.34 M(+23.8%) | $11.70 M(+2.9%) |
| Dec 2021 | $11.37 M(+14.9%) | $2.70 M(-5.1%) | $11.37 M(+1.4%) |
| Sept 2021 | - | $2.84 M(+0.9%) | $11.21 M(+4.9%) |
| June 2021 | - | $2.82 M(-6.4%) | $10.69 M(+3.3%) |
| Mar 2021 | - | $3.01 M(+18.6%) | $10.34 M(+4.6%) |
| Dec 2020 | $9.89 M(+6.4%) | $2.54 M(+9.4%) | $9.89 M(+2.3%) |
| Sept 2020 | - | $2.32 M(-6.2%) | $9.67 M(+2.7%) |
| June 2020 | - | $2.47 M(-3.3%) | $9.41 M(+1.2%) |
| Mar 2020 | - | $2.56 M(+10.5%) | $9.30 M(+0.0%) |
| Dec 2019 | $9.29 M(-1.0%) | $2.31 M(+11.9%) | $9.29 M(+0.3%) |
| Sept 2019 | - | $2.07 M(-12.3%) | $9.27 M(+0.1%) |
| June 2019 | - | $2.36 M(-7.7%) | $9.26 M(+2.3%) |
| Mar 2019 | - | $2.55 M(+11.6%) | $9.05 M(-3.7%) |
| Dec 2018 | $9.39 M(-20.1%) | $2.29 M(+11.0%) | $9.39 M(-3.9%) |
| Sept 2018 | - | $2.06 M(-3.9%) | $9.77 M(-8.3%) |
| June 2018 | - | $2.15 M(-25.9%) | $10.65 M(-10.8%) |
| Mar 2018 | - | $2.90 M(+8.6%) | $11.94 M(+1.6%) |
| Dec 2017 | $11.75 M(-8.2%) | $2.67 M(-9.3%) | $11.75 M(+3.3%) |
| Sept 2017 | - | $2.94 M(-14.3%) | $11.37 M(+1.6%) |
| June 2017 | - | $3.43 M(+26.8%) | $11.20 M(+4.8%) |
| Mar 2017 | - | $2.71 M(+18.2%) | $10.68 M(-26.0%) |
| Dec 2016 | $12.80 M(-57.3%) | $2.29 M(-17.3%) | $14.43 M(-16.0%) |
| Sept 2016 | - | $2.77 M(-5.1%) | $17.18 M(-12.2%) |
| June 2016 | - | $2.92 M(-54.8%) | $19.56 M(-22.9%) |
| Mar 2016 | - | $6.46 M(+28.3%) | $25.38 M(-15.4%) |
| Dec 2015 | $30.01 M(-2.6%) | $5.03 M(-2.2%) | $30.01 M(-4.6%) |
| Sept 2015 | - | $5.15 M(-41.1%) | $31.47 M(-8.0%) |
| June 2015 | - | $8.74 M(-21.2%) | $34.22 M(+3.9%) |
| Mar 2015 | - | $11.09 M(+70.7%) | $32.92 M(+6.9%) |
| Dec 2014 | $30.81 M(+42.5%) | $6.50 M(-17.7%) | $30.81 M(+1.9%) |
| Sept 2014 | - | $7.89 M(+6.0%) | $30.24 M(+8.4%) |
| June 2014 | - | $7.45 M(-17.0%) | $27.90 M(+12.6%) |
| Mar 2014 | - | $8.97 M(+51.2%) | $24.78 M(+14.7%) |
| Dec 2013 | $21.61 M(-3.1%) | $5.93 M(+6.7%) | $21.61 M(+3.4%) |
| Sept 2013 | - | $5.56 M(+28.6%) | $20.90 M(-1.8%) |
| June 2013 | - | $4.32 M(-25.5%) | $21.29 M(-1.9%) |
| Mar 2013 | - | $5.80 M(+11.1%) | $21.71 M(-2.7%) |
| Dec 2012 | $22.32 M(-19.4%) | $5.22 M(-12.2%) | $22.32 M(-5.0%) |
| Sept 2012 | - | $5.95 M(+25.7%) | $23.49 M(-0.1%) |
| June 2012 | - | $4.73 M(-26.2%) | $23.51 M(-15.0%) |
| Mar 2012 | - | $6.41 M(+0.3%) | $27.65 M(-10.4%) |
| Dec 2011 | $27.69 M(-10.1%) | $6.39 M(+7.0%) | $30.87 M(-3.0%) |
| Sept 2011 | - | $5.98 M(-32.6%) | $31.83 M(-9.5%) |
| June 2011 | - | $8.87 M(-8.0%) | $35.16 M(+2.9%) |
| Mar 2011 | - | $9.63 M(+31.2%) | $34.15 M(+10.9%) |
| Dec 2010 | $30.79 M | $7.35 M(-21.1%) | $30.81 M(-13.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $9.31 M(+18.3%) | $35.65 M(+12.2%) |
| June 2010 | - | $7.87 M(+25.1%) | $31.78 M(+13.0%) |
| Mar 2010 | - | $6.29 M(-48.4%) | $28.11 M(+19.9%) |
| Dec 2009 | $23.40 M(+175.5%) | $12.19 M(+124.4%) | $23.45 M(+81.6%) |
| Sept 2009 | - | $5.43 M(+29.4%) | $12.91 M(+37.2%) |
| June 2009 | - | $4.20 M(+158.9%) | $9.41 M(+24.0%) |
| Mar 2009 | - | $1.62 M(-1.9%) | $7.59 M(-10.6%) |
| Dec 2008 | $8.49 M(-20.2%) | $1.65 M(-14.6%) | $8.49 M(-8.9%) |
| Sept 2008 | - | $1.94 M(-18.6%) | $9.32 M(-20.4%) |
| June 2008 | - | $2.38 M(-5.7%) | $11.71 M(+3.7%) |
| Mar 2008 | - | $2.52 M(+1.7%) | $11.29 M(+6.1%) |
| Dec 2007 | $10.65 M(+125.8%) | $2.48 M(-42.6%) | $10.64 M(+7.5%) |
| Sept 2007 | - | $4.33 M(+120.7%) | $9.90 M(+50.7%) |
| June 2007 | - | $1.96 M(+4.7%) | $6.57 M(+16.3%) |
| Mar 2007 | - | $1.87 M(+7.9%) | $5.65 M(+19.8%) |
| Dec 2006 | $4.71 M(+192.6%) | $1.74 M(+73.6%) | $4.71 M(+35.6%) |
| Sept 2006 | - | $999.80 K(-3.8%) | $3.48 M(+15.3%) |
| June 2006 | - | $1.04 M(+10.7%) | $3.02 M(+29.1%) |
| Mar 2006 | - | $939.20 K(+88.2%) | $2.34 M(+44.9%) |
| Dec 2005 | $1.61 M(+111.0%) | $499.10 K(-7.2%) | $1.61 M(+17.9%) |
| Sept 2005 | - | $538.10 K(+50.0%) | $1.37 M(+34.9%) |
| June 2005 | - | $358.80 K(+66.5%) | $1.01 M(+22.1%) |
| Mar 2005 | - | $215.50 K(-15.4%) | $830.00 K(+8.7%) |
| Dec 2004 | $763.60 K(+11.4%) | $254.70 K(+38.2%) | $763.60 K(+16.6%) |
| Sept 2004 | - | $184.30 K(+5.0%) | $654.90 K(-2.5%) |
| June 2004 | - | $175.50 K(+17.7%) | $671.90 K(-4.8%) |
| Mar 2004 | - | $149.10 K(+2.1%) | $705.90 K(+3.0%) |
| Dec 2003 | $685.40 K(-24.8%) | $146.00 K(-27.5%) | $685.40 K(+6.5%) |
| Sept 2003 | - | $201.30 K(-3.9%) | $643.60 K(-4.4%) |
| June 2003 | - | $209.50 K(+62.9%) | $673.10 K(+0.6%) |
| Mar 2003 | - | $128.60 K(+23.4%) | $669.10 K(-26.6%) |
| Dec 2002 | $912.00 K(-44.5%) | $104.20 K(-54.9%) | $911.90 K(-28.9%) |
| Sept 2002 | - | $230.80 K(+12.3%) | $1.28 M(-10.9%) |
| June 2002 | - | $205.50 K(-44.7%) | $1.44 M(-9.7%) |
| Mar 2002 | - | $371.40 K(-21.6%) | $1.59 M(-3.1%) |
| Dec 2001 | $1.64 M(-34.6%) | $474.00 K(+22.4%) | $1.64 M(-11.5%) |
| Sept 2001 | - | $387.40 K(+7.8%) | $1.86 M(-26.1%) |
| June 2001 | - | $359.30 K(-14.9%) | $2.51 M(-5.0%) |
| Mar 2001 | - | $422.20 K(-38.6%) | $2.64 M(+4.9%) |
| Dec 2000 | $2.51 M(+145.5%) | $687.90 K(-34.0%) | $2.52 M(+37.5%) |
| Sept 2000 | - | $1.04 M(+112.8%) | $1.83 M(+132.0%) |
| June 2000 | - | $490.20 K(+63.6%) | $789.90 K(+163.6%) |
| Mar 2000 | - | $299.70 K | $299.70 K |
| Dec 1999 | $1.02 M(+138.8%) | - | - |
| Dec 1998 | $428.20 K(+93.2%) | - | - |
| Mar 1998 | $221.60 K(-11.9%) | - | - |
| Mar 1997 | $251.60 K(-2.1%) | - | - |
| Mar 1996 | $257.10 K | - | - |
FAQ
- What is Caladrius Biosciences annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Caladrius Biosciences?
- What is Caladrius Biosciences annual SG&A year-on-year change?
- What is Caladrius Biosciences quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Caladrius Biosciences?
- What is Caladrius Biosciences quarterly SG&A year-on-year change?
- What is Caladrius Biosciences TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Caladrius Biosciences?
- What is Caladrius Biosciences TTM SG&A year-on-year change?
What is Caladrius Biosciences annual selling, general & administrative expenses?
The current annual SG&A of CLBS is $11.37 M
What is the all time high annual SG&A for Caladrius Biosciences?
Caladrius Biosciences all-time high annual selling, general & administrative expenses is $30.81 M
What is Caladrius Biosciences annual SG&A year-on-year change?
Over the past year, CLBS annual selling, general & administrative expenses has changed by +$1.48 M (+14.94%)
What is Caladrius Biosciences quarterly selling, general & administrative expenses?
The current quarterly SG&A of CLBS is $3.95 M
What is the all time high quarterly SG&A for Caladrius Biosciences?
Caladrius Biosciences all-time high quarterly selling, general & administrative expenses is $12.19 M
What is Caladrius Biosciences quarterly SG&A year-on-year change?
Over the past year, CLBS quarterly selling, general & administrative expenses has changed by +$1.10 M (+38.83%)
What is Caladrius Biosciences TTM selling, general & administrative expenses?
The current TTM SG&A of CLBS is -$1.88 B
What is the all time high TTM SG&A for Caladrius Biosciences?
Caladrius Biosciences all-time high TTM selling, general & administrative expenses is $35.65 M
What is Caladrius Biosciences TTM SG&A year-on-year change?
Over the past year, CLBS TTM selling, general & administrative expenses has changed by -$1.89 B (-16829.50%)